GPEx® A Flexible Method for the Rapid Generation of Stable, High Expressing, Antibody Producing Mammalian Cell Lines

Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume XI)


A versatile system has been developed, which is capable of transferring genes of interest into a wide variety of mammalian host cells and offers a number of advantages over the other methods for production of antibodies. These advantages include; (1) Shorter timelines, (2) Improved consistency, (3) Higher specific productivities, (4) Better genetic stabilities, (5) Increased flexibility and (6) Ability to work on any cell line.

The GPEx® method utilizes replication defective retroviral vectors, derived from Moloney Murine Leukemia virus (MLV) and pseudotyped with Vesicular Stomatitis Virus Glycoprotein (VSV-G), to stably insert single copies of genes at multiple genomic locations into dividing cells. Retrovectors deliver genes coded as RNA that, after entering the cell, are reverse transcribed to DNA and integrated stably into the genome of the host cell. Two enzymes, reverse transcriptase and integrase, provided transiently in the vector particle, perform this function. These integrated genes are maintained through subsequent cell divisions as if they were endogenous cellular genes. By controlling the number of retrovector particles accessing the cell, multiple gene insertion (desirable for high yielding cell cultures) can be achieved without any of the traditional amplification steps. This chapter describes the use of the GPEx® technology for transferring genes into Chinese Hamster Ovary (CHO) cells, for the purpose of consistently producing cell lines with high antibody production levels in a short amount of time (Fig. 4-1).


Murine Leukemia Virus Chinese Hamster Ovary Cell Line Antibody Variant Vesicular Stomatitis Virus Glycoprotein Cell Line Development 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Andrake MD, Skalka AM (1996) Retroviral integrase, putting the pieces together. J Biol Chem 271(33):19633–19636PubMedCrossRefGoogle Scholar
  2. Barnes LM, Bentley CM, Dickson AJ (2004) Molecular definition of predictive indicators of stable protein expression in recombinant NS0 myeloma cells. Biotechnol Bioeng 85(2):115–121PubMedCrossRefGoogle Scholar
  3. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK (1993) Vesicular stomatitis virus G glycoprotein-pseudotyped retroviral vectors: concentration to a very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A 90:8033–8037PubMedCrossRefGoogle Scholar
  4. Kim NS, Kim SJ, Lee GM (1998) Clonal variability within dihydrofolate reductase-mediated gene amplified Chinese hamster ovary cells: stability in the absence of selection pressure. Biotechnol Bioeng 60(6):679–688PubMedCrossRefGoogle Scholar
  5. Mitchell RS, Beitzel BF, Schroder ARW, Shinn P, Chen H, Berry CC, Ecker JR, Bushman FD (2004) Retroviral DNA, integration: ASLV, HIV and MLV show distinct target site preferences. PLoS Biol 2(8):1127–1137CrossRefGoogle Scholar
  6. Pear W (1996) Transient transfection methods for preparation of high-titer retroviral supernatants. In: Current protocols in molecular biology, vol 2, edited by Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K. Wiley, New York, 9.11.1–9.11.18Google Scholar
  7. Schlegel R, Tralka TS, Willingham MC, Pastan I (1983) Inhibition of VSV binding and infectivity by phosphatidylserine: is phosphatidylserine a VSV-binding site? Cell 32:639–646PubMedCrossRefGoogle Scholar
  8. Strutzenberger K, Borth N, Kunert R, Steinfellner W, Katinger H (1999) Changes during subclone development and ageing of human antibody-producing recombinant CHO cells. J Biotechnol 69:215–226PubMedCrossRefGoogle Scholar
  9. Wu X, Li Y, Crise B, Burgess SM (2003) Transcription start regions in the human genome are favored targets for MLV integration. Science 300:1749–1751PubMedCrossRefGoogle Scholar
  10. Yee JK, Friedmann T, Burns JC (1994) Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol 43:99–112PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2010

Authors and Affiliations

  1. 1.Cell Line EngineeringGala Biotech, A Catalent Pharma Solutions CompanyMiddletonUSA

Personalised recommendations